Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLloyds Regulatory News (LLOY)

Share Price Information for Lloyds (LLOY)

Share Price is delayed by 15 minutes
Get Live Data
99.32    0.42 (0.42%)
Bid:
99.30
Ask:
99.34
Spread: 0.04 (0.04%)
Market Cap: £57.88b
LLOY Live PriceLast checked at - London Stock Exchange

Intraday Lloyds Share Chart

Board Changes

22 Feb 2024 07:00

RNS Number : 9936D
Lloyds Banking Group PLC
22 February 2024
 

22 February 2024

LLOYDS BANKING GROUP: BOARD CHANGES

Lloyds Banking Group plc ("Group") announces that Alan Dickinson, having served nine years as a non-executive director as of September 2023, has informed the Board that he intends to step down as Deputy Chair and a non-executive director of the Group at its 2024 annual general meeting.

The Group is pleased to announce that Nathan Bostock will be appointed a non-executive director of the Group and, subject to regulatory approval, Chair of Lloyds Bank Corporate Markets plc, in each case with effect from 1 August 2024. Nathan was Chief Executive Officer of Santander UK from 2014 until 2022. Prior to joining Santander, Nathan was an executive director and Group Chief Financial Officer of The Royal Bank of Scotland plc ("RBS") and previously held the post of Chief Risk Officer at RBS.

Sir Robin Budenberg, Group Chair, said "We will miss the enormous contribution Alan has made to the Group over many years including long-term roles on all our committees and spells as Chair of the Risk and Remuneration Committees. The tremendous insights he has brought to his roles have been particularly valued during a tenure as Deputy Chair and Senior Independent Director which has included Chair and Group Chief Executive successions and the challenges created by the COVID-19 pandemic and the ongoing cost of living increases. At the same time, we look forward to welcoming Nathan to the Group. Nathan brings extensive capital markets and wider financial services experience, in particular from his chief executive and chief risk officer roles. His deep knowledge of the UK banking market will be invaluable to his roles with the Group."

Further information on Nathan Bostock is set out below. There is no other information to be disclosed under paragraph 9.6.13R of the Listing Rules in relation to Nathan's appointment.

Biographical details

Nathan Bostock was Chief Executive Officer of Santander UK from 2014 until 2022 and then Head of Investment Platforms at Banco Santander until his retirement from Santander last year. Prior to joining Santander, Nathan was an executive director and Group Chief Financial Officer of RBS and previously held the post of Chief Risk Officer at RBS. Before joining RBS, Nathan was an executive director of Abbey National plc (now Santander UK) from 2005 until 2009. He held a number of senior positions at Abbey National plc including CEO - Financial Markets and Corporate Banking, CEO - Financial Markets and Portfolio Business Unit and Chief Operating Officer - Abbey National Treasury Services.

Nathan Bostock is currently a non-executive director of Centrica plc and Chair of its Audit and Risk Committee. Nathan is a chartered accountant.

- END -

For further information:

Investor Relations

Douglas Radcliffe

Group Investor Relations Director

Email: douglas.radcliffe@lloydsbanking.com

 

Group Corporate Affairs

Matt Smith

Head of Media Relations

Email: matt.smith@lloydsbanking.com

 

+44 (0) 20 7356 1571

 

 

 

 

+44 (0) 7788 352 487

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOASEUFMFELSEIE
Date   Source Headline
29th Feb 20245:18 pmRNSTotal Voting Rights
29th Feb 20244:21 pmRNS2023 Form 20F Filed
29th Feb 20242:30 pmRNSTotal Voting Rights
29th Feb 20248:32 amRNS2023 Annual Report and Accounts
29th Feb 20248:32 amRNS2023 Annual Report and Accounts
28th Feb 20245:57 pmRNSTransaction in Own Shares
27th Feb 20245:59 pmRNSTransaction in Own Shares
26th Feb 20246:15 pmRNSTransaction in Own Shares
26th Feb 202411:00 amRNSDirector/PDMR Shareholding
23rd Feb 20246:10 pmRNSTransaction in Own Shares
23rd Feb 202411:50 amRNSPublication of Suppl.Prospcts
23rd Feb 20247:34 amRNSShare Buyback Programme Commences
22nd Feb 20244:13 pmRNS2023 Form 20F Filed
22nd Feb 20247:00 amRNSBoard Changes
22nd Feb 20247:00 amRNS2023 Full Year Results
22nd Feb 20247:00 amRNS2023 Annual Report and Accounts
20th Feb 20242:05 pmRNSReplacement Block listing Interim Review
20th Feb 20242:00 pmRNSReplacement Block listing Interim Review
15th Feb 20247:00 amRNSBoard Change
31st Jan 20243:56 pmRNSTotal Voting Rights
25th Jan 20245:07 pmRNSBoard Committee Change
11th Jan 20242:00 pmRNSDirector/PDMR Shareholding
5th Jan 20241:50 pmRNSPublication of Final Terms
2nd Jan 202412:00 pmRNSBlock listing Interim Review
29th Dec 202310:30 amRNSTotal Voting Rights
18th Dec 20232:30 pmRNSBoard Committee Change
18th Dec 20232:00 pmRNSDirector/PDMR Shareholding
12th Dec 20234:00 pmRNSDirector/PDMR Shareholding
30th Nov 20232:00 pmRNSTotal Voting Rights
20th Nov 20232:00 pmRNSBlock Listing of Shares
10th Nov 20234:00 pmRNSDirector/PDMR Shareholding
6th Nov 20233:57 pmRNSPublication of Final Terms
31st Oct 202311:20 amRNSTotal Voting Rights
26th Oct 20233:47 pmRNSPublication of Suppl.Prospcts
26th Oct 20231:02 pmRNSPublication of Suppl.Prospcts
26th Oct 202312:59 pmRNSPublication of Suppl.Prospcts - Correction
25th Oct 202312:09 pmRNSPublication of Suppl.Prospcts
25th Oct 202311:57 amRNS2023 Q3 Interim Management Statement
25th Oct 20237:00 amRNS2023 Q3 Interim Management Statement
11th Oct 20232:00 pmRNSDirector/PDMR Shareholding
22nd Sep 20232:00 pmRNSDirector/PDMR Shareholding
21st Sep 20231:28 pmRNSPublication of Final Terms
20th Sep 20232:00 pmRNSDirector/PDMR Shareholding
15th Sep 20232:00 pmRNSDirector/PDMR Shareholding
13th Sep 20232:00 pmRNSBoard and Committee changes
13th Sep 20231:45 pmRNSDirector/PDMR Shareholding
13th Sep 20239:20 amRNS2023 Half-Year Results
31st Aug 202312:00 pmRNSTotal Voting Rights
29th Aug 20237:21 amRNSCompletion of £2 billion Share Buyback Programme
25th Aug 20235:51 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.